PRP for ovarian rejuvenation

What ovarian PRP involves

Platelet-rich plasma is produced from the patient's own blood. Blood is drawn and processed in a centrifuge to separate platelets from red cells and plasma. The resulting PRP concentrate contains a high density of platelets and the growth factors they release, including PDGF, VEGF, TGF-beta, IGF-1, EGF, and FGF.

These growth factors are thought to activate signaling pathways that can recruit dormant primordial follicles into the growing pool. The ovarian cortex contains a reserve of primordial follicles normally held in arrest; localized growth factor delivery may partially overcome this arrest and temporarily restore ovarian activity.

Ovarian PRP is distinct from endometrial PRP, which targets the uterine lining. The injection site, preparation, and clinical goals are different. Always confirm with your clinic which procedure is being proposed.

How ovarian PRP is performed

1. Blood draw: 20 to 60 mL of venous blood is collected, typically from the arm.
2. Centrifugation: the sample is spun to separate platelet-rich plasma from red cells. Some protocols use a double-spin method to concentrate platelets further.
3. Activation (optional): some clinics activate PRP with calcium chloride or thrombin before injection; others inject unactivated PRP. There is no consensus on which approach produces better outcomes.
4. Injection: under transvaginal ultrasound guidance and sedation or local anesthesia, 1 to 2 mL of PRP is injected into each ovary, targeting the cortical region. The procedure takes 20 to 40 minutes.
5. Recovery: same-day discharge. Mild pelvic discomfort is common for 24 to 48 hours.
6. Monitoring: AMH, FSH, and antral follicle count (AFC) are measured 4 to 8 weeks after the procedure to assess response. IVF stimulation, if planned, is typically started within the response window.

Protocols vary between clinics, including centrifugation speed, PRP volume, injection site, number of treatments, and whether one or both ovaries are injected. There is no standardized protocol at this stage of the evidence base.

What the evidence shows

Ovarian PRP was first reported in the reproductive medicine literature in 2016 by Pantos et al. (Greece), describing three patients with premature ovarian insufficiency who showed improvements in hormonal markers following intraovarian PRP injection. Published evidence since then consists primarily of case reports, case series, and small pilot studies with sample sizes ranging from a few patients to under 100.

The absence of large, well-powered randomized controlled trials means the current evidence base cannot reliably quantify who responds, by how much, or for how long. Reported findings from the published literature include:

1. AMH improvement: measurable increases in AMH have been reported in 30 to 60% of treated patients in published series, with the timing of testing influencing results significantly.
2. FSH reduction: some patients with elevated FSH show transient reductions after treatment.
3. Follicular activity: a proportion of patients who had no or very few antral follicles before treatment have follicles detectable on ultrasound at 4 to 8 weeks post-injection.
4. Menstrual recovery: in patients with POI and absent periods, some series report return of menstruation after treatment, though this is not consistent.
5. Pregnancy and live birth: case reports and small series document IVF cycles and natural pregnancies following ovarian PRP in patients with very low reserve. These are not sufficient to establish reliable pregnancy or live birth rates.

The key limitation is selection and reporting bias: clinics and researchers are more likely to publish positive outcomes. Patients who did not respond are systematically underrepresented in the published literature.

No large-scale RCT has established a clear live birth rate benefit over expectant management or conventional IVF for any specific patient group. Ovarian PRP remains in the investigational category under the frameworks of the American Society for Reproductive Medicine (ASRM) and most major national reproductive medicine bodies.

Realistic expectations

Response to ovarian PRP, when it occurs, is typically:

1. Transient: improvements in AMH or follicle activity are generally observed for 3 to 12 months. IVF stimulation, if planned, should occur within this window.
2. Variable: a substantial proportion of patients see no measurable change. Published series suggest non-response rates of 40 to 70% depending on the patient population and outcome definition used.
3. Not predictable: there are no validated biomarkers that reliably identify in advance which patients will respond. Age, baseline AMH, AFC, and duration of ovarian insufficiency have been proposed as factors, but none have been validated for clinical prediction.
4. Not a cure: ovarian PRP does not regenerate or permanently restore ovarian reserve. Any eggs obtained during the response window carry the chromosomal profile expected for the patient's age.

A response in AMH improvement does not guarantee retrievable eggs, fertilizable embryos, or a live birth. Each step in the IVF process after PRP carries the same attrition as any IVF cycle.

Who may be considered for ovarian PRP

Ovarian PRP is offered at specialist clinics to patients in whom conventional IVF stimulation has produced very few or no eggs, and who have not yet moved to donor eggs. Typical profiles:

1. Diminished ovarian reserve (DOR): AMH below 1.0 ng/mL, AFC below 5 to 7, normal ovulatory cycles still present.
2. Poor ovarian responder: fewer than 4 eggs retrieved in a previous stimulated IVF cycle despite adequate FSH dosing.
3. Premature ovarian insufficiency (POI): FSH above 25 IU/L, irregular or absent cycles, age under 40; own egg IVF previously unsuccessful or untried.
4. Surgical or iatrogenic diminished reserve: ovarian reserve depleted by surgery, chemotherapy, or radiotherapy, with some residual ovarian tissue present.

Ovarian PRP is not a first-line option. It is typically considered after conventional IVF has failed due to poor response, or before attempting donor eggs when the patient wants to make one more attempt with their own genetic material.

When ovarian PRP is not appropriate

1. Complete ovarian failure with no residual follicles: if serial ultrasound and hormonal assessment confirm no remaining follicular activity and FSH is consistently above 40 IU/L with absent cycles over several years, there is no follicle pool for PRP to act on. Donor egg IVF is the appropriate discussion.
2. Active gynecological malignancy: PRP involves injection into ovarian tissue and should not be performed in patients with active ovarian or other gynecological cancer.
3. Platelet disorders or anticoagulant therapy: conditions affecting platelet function or patients on therapeutic anticoagulation may not produce viable PRP and carry increased procedural bleeding risk.
4. Patients for whom donor eggs offer a clear path: donor egg IVF has established, substantially higher success rates. Where the patient is ready to consider donor eggs, pursuing PRP first delays a treatment with a reliably better probability of live birth.

How ovarian PRP compares to other approaches for low reserve

1. DHEA supplementation: low to moderate evidence; some RCT data; used as daily oral supplementation for 3 or more months before IVF stimulation in DOR.
2. CoQ10 supplementation: low evidence; mixed RCT data; mitochondrial support for egg quality in DOR and advanced age.
3. Growth hormone adjuvant: moderate evidence; several RCTs in poor responders; added to IVF stimulation protocol in confirmed poor responders.
4. Ovarian PRP: very low evidence; case series only; investigational, attempted before donor egg decision in selected patients.
5. Donor egg IVF: high evidence; established outcomes data; definitive solution where own egg IVF has failed or reserve is exhausted.

None of the adjuvant approaches for diminished reserve have the evidentiary weight of donor egg IVF. DHEA and growth hormone have stronger RCT support than PRP, but all three fall short of the live birth rate data available for donor egg IVF.

Ovarian PRP cost

Additional costs sometimes not included, confirm with your clinic:

1. Pre-procedure testing: AMH, AFC, hormone panel, infectious disease screen
2. Follow-up AMH and AFC monitoring at 4 to 8 weeks post-procedure
3. Repeat PRP treatment if a second cycle is recommended
4. IVF stimulation and egg retrieval following PRP, if planned as a combined protocol
5. Anesthesia or sedation fee (sometimes billed separately)

Frequently asked questions about PRP for ovarian rejuvenation

Is ovarian PRP the same as ovarian rejuvenation?

The terms are often used interchangeably but are not identical. Ovarian rejuvenation refers broadly to any intervention aimed at restoring or improving ovarian function; PRP is one method used to attempt this. Other approaches, such as stem cell therapy, are also sometimes described as ovarian rejuvenation. When a clinic uses the term, confirm exactly which procedure they are proposing.

How soon after PRP can I start IVF?

Most clinics recommend waiting 4 to 8 weeks after the procedure before starting IVF stimulation, to allow time for any follicular response to develop and to confirm it on AMH and AFC measurements. Starting too early reduces the chance of capturing any benefit the procedure may have produced.

Can ovarian PRP restore my periods if I have POI?

Some patients with premature ovarian insufficiency have reported return of menstruation after ovarian PRP, and this has been documented in published case series. It does not occur in all patients and cannot be predicted in advance. Return of periods alone does not confirm sufficient reserve for IVF; hormonal and ultrasound assessment should guide that decision.

Do I need more than one PRP treatment?

Some clinics offer repeat injections if a partial response is seen but not enough to proceed with IVF, or if the initial response was temporary. There is no evidence that multiple treatments produce cumulative benefit; this practice is based on clinical judgment at individual centers rather than published data.

What happens if ovarian PRP does not work?

If no measurable response is observed at 4 to 8 weeks, most clinics recommend reassessing the diagnosis and discussing alternative options. For patients who have not yet considered donor egg IVF, this is usually the next conversation. A non-response does not rule out a response to a second attempt, but provides no predictive data suggesting one will occur.

Is ovarian PRP covered by insurance?

In most countries, ovarian PRP is not covered by public health systems or standard fertility insurance plans because it is classified as experimental. Patients should assume full out-of-pocket costs and verify with their insurer before committing to treatment.

What is the difference between ovarian PRP and endometrial PRP?

Endometrial PRP is injected into the uterine cavity to improve uterine lining receptivity, typically in patients with thin endometrium or implantation failure. Ovarian PRP targets ovarian tissue to try to improve follicle activity. They are different procedures with different indications, injection sites, and evidence bases. Some clinics offer both; confirm which is being proposed for your specific diagnosis.